Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.70 USD
Change Today -0.06 / -0.34%
Volume 265.8K
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

aegerion pharmaceuticals inc (AEGR) Snapshot

Open
$17.56
Previous Close
$17.76
Day High
$18.03
Day Low
$17.47
52 Week High
10/3/14 - $36.19
52 Week Low
07/6/15 - $16.68
Market Cap
506.6M
Average Volume 10 Days
545.6K
EPS TTM
$-1.43
Shares Outstanding
28.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AEGERION PHARMACEUTICALS INC (AEGR)

aegerion pharmaceuticals inc (AEGR) Related Businessweek News

No Related Businessweek News Found

aegerion pharmaceuticals inc (AEGR) Details

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products include JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults. Its products also comprise MYALEPT (metreleptin), a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. The company distributes its products directly to patients and other purchasers through a specialty pharmacy. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

307 Employees
Last Reported Date: 08/17/15
Founded in 2005

aegerion pharmaceuticals inc (AEGR) Top Compensated Officers

Chief Medical Officer
Total Annual Compensation: $405.0K
Chief Performance Officer
Total Annual Compensation: $341.3K
Chief Regulatory Officer and Senior Vice Pres...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2014.

aegerion pharmaceuticals inc (AEGR) Key Developments

Aegerion Pharmaceuticals, Inc. announced delayed 10-Q filing

On 08/11/2015, Aegerion Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Aegerion Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reiterates Earnings Guidance for the Year 2015

Aegerion Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company’s net product sales were $64,197,000 compared to $36,014,000 a year ago. Loss from operations was $4,507,000 compared to $9,416,000 a year ago. Loss before provision for income taxes was $10,460,000 compared to $9,517,000 a year ago. Net loss was $10,714,000 or $0.37 per basic and diluted share compared to $9,622,000 or $0.33 per basic and diluted share a year ago. Non-GAAP net income was $6,594,000 or $0.23 per basic and diluted share compared to Non-GAAP net loss of $1,651,000 or $0.06 per basic and diluted share a year ago. For the six months, the company’s net product sales were $123,581,000 compared to $62,987,000 a year ago. Loss from operations was $13,687,000 compared to $24,790,000 a year ago. Loss before provision for income taxes was $26,086,000 compared to $25,069,000 a year ago. Net loss was $26,539,000 or $0.93 per basic and diluted share compared to $25,398,000 or $0.86 per basic and diluted share a year ago. Non-GAAP net income was $8,171,000 or $0.29 per basic and diluted share compared to Non-GAAP net loss of $8,899,000 or $0.30 per basic and diluted share a year ago. The company reiterated earnings guidance for the year 2015. For the year, the company expects global net product sales of JUXTAPID to be between $195 million and $215 million. The company expects global net product sales of MYALEPT to be between $10 million and $20 million. The company expects to generate positive cash flow from operations for the full year of 2015.

Aegerion Pharmaceuticals Provides Revenue Guidance for the Second Quarter of 2015

Aegerion Pharmaceuticals provided revenue guidance for the second quarter of 2015. For the quarter, the company expects net product sales of between $63 and $64 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEGR:US $17.70 USD -0.06

AEGR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Isis Pharmaceuticals Inc $52.10 USD +0.53
View Industry Companies
 

Industry Analysis

AEGR

Industry Average

Valuation AEGR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEGERION PHARMACEUTICALS INC, please visit www.aegerion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.